Voices
Yüksel Ürün
Yüksel Ürün/X

Yüksel Ürün: FDA Approves Intravesical Gemcitabine System for BCG-Unresponsive NMIBC

Yüksel Ürün, Medical Oncology Professor at Ankara University School of Medicine, shared a post on X:

“FDA just approved intravesical gemcitabine system for BCG-unresponsive NMIBC with CIS ± papillary tumors. CR rate 82%, half lasting ≥12 months. A new door for patients.”

FDA

More posts featuring Yüksel Ürün on OncoDaily.

bladder cancer cancer Headlines NMIBC OncoDaily Oncology Yüksel Ürün